DiaGenic awarded for best article in 2011
DiaGenic Press release JAD award 2012Highly ranked Journal of Alzheimer's Disease (JAD) today announced that Anders Lönneborg and DiaGenic has been chosen as recipient of the 2011 Alzheimer Award. The article «A Novel Blood Test for the Early Detection of Alzheimer's Disease" which covers the development of the diagnostic Alzheimer test ADtect® was voted for by a majority of the Associate Editors of JAD as the most outstanding article in 2011. This prestigious award is supported by IOS Press and Elan Pharmaceuticals.
"Journal of Alzheimer's Disease is a highly recognised journal in the Alzheimer's disease field. The award provides further recognition from leading experts to the development of DiaGenic’s Alzheimer test ADtect®", says Magnus Sjögren MD PhD, CMO of DiaGenic.
"This recognition further strengthens DiaGenic’s position among clinicians and pharmaceutical companies, and confirms our position as a leader in blood based biomarkers within Alzheimer’s disease", says Henrik Lund MD PhD, CEO of DiaGenic.
Please see press release attached.
Abstract of the article can be found on the following link:
About Alzheimer’s Disease
According to the Alzheimer's Association, deaths attributed to the disease have increased by more than 46% between 2000 and 2006. Today, in the US alone, 5.3 million people have Alzheimer’s disease, and the annual cost of the disease is $172 billion. It is the 6thleading cause of death, and its mortality rates are expected to rise as the baby boomer population ages. In last year’s World Alzheimer Report, Alzheimer’s Disease International estimated that there are 35.6 million people living with dementia worldwide in 2010, increasing to 65.7 million by 2030 and 115.4 million by 2050.
Henrik Lund, CEO
Telephone: 47 90971219
About DiaGenic ASA
DiaGenic seeks to create value for patients, partners, and investors by developing innovative and more patient friendly methods for early detection of diseases utilizing DiaGenic’s unique concept. The concept implies that a disease evokes systemic responses in the blood unique for the disease, and which can be measured by using blood samples.
DiaGenic is a world leader in identifying these gene expression signatures in peripheral blood and is focused on the development of biomarkers in the field of Alzheimer’s disease and Parkinson’s disease. DiaGenic’s Alzheimer’s disease development program includes the CE marked diagnostic test ADtect®, for detection of mild to moderate Alzheimer’s disease, and MCItect®which is under development for identifying patients with very early stages of Alzheimer’s disease (prodromal AD).
DiaGenic’s concept is protected through an extensive patent portfolio. DiaGenic promotes its products and services towards leading pharmaceutical, imaging and diagnostic companies. DiaGenic is located in Norway and listed on the Oslo Stock Exchange. For more information please visit: www.diagenic.com